Literature DB >> 16132039

Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly.

P F T Cezar-de-Mello1, V Nascimento-Silva, C G Villela, I M Fierro.   

Abstract

Angiogenesis, the growth of new capillaries from pre-existing ones, occurs through dynamic functions of the endothelial cells (EC), including migration, which is essential to achieve an organized formation of the vessel sprout. We demonstrated previously that an aspirin-triggered lipoxin analog, 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4 (ATL-1), inhibits vascular endothelial growth factor (VEGF)-induced EC migration. In the present study, we investigated the effects of ATL-1 in the actin cytoskeleton reorganization of EC stimulated with VEGF. Pretreatment of EC with ATL-1 caused a reduction in VEGF-induced stress fibers and therefore reduced the intracellular content of filamentous actin. A concomitant impairment in stress-activated protein kinase (SAPK2/p38) phosphorylation suggests that ATL inhibition of VEGF-stimulated actin polymerization involves the SAPK2/p38 pathway. Moreover, ATL-1 treatment inhibited focal adhesion clustering due to inhibition of focal adhesion kinase (FAK) phosphorylation and the subsequent association of FAK with the actin cytoskeleton. This final event, which ultimately allows cell migration, was reverted by an LX receptor antagonist, but not by a cys-LT1R antagonist, indicating an effect via the G-protein-linked LXA4 receptor. Together our results provide evidence that ATL-1 inhibits EC migration via the concerted inhibition of actin polymerization and proper assembly of focal adhesions, supporting a role for these novel lipid mediators as angiogenesis modulators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16132039     DOI: 10.1038/sj.onc.1209002

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes.

Authors:  Vitaliy Starosta; Konrad Pazdrak; Istvan Boldogh; Tetyana Svider; Alexander Kurosky
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 3.  Lipid mediators in the regulation of endothelial barriers.

Authors:  Pratap Karki; Konstantin G Birukov
Journal:  Tissue Barriers       Date:  2017-10-30

Review 4.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis.

Authors:  Naoto Yoshizuka; Rebecca M Chen; Zeyu Xu; Rong Liao; Lixin Hong; Wen-Yuan Hu; Guoliang Yu; Jiahuai Han; Longchuan Chen; Peiqing Sun
Journal:  Mol Cell Biol       Date:  2011-11-28       Impact factor: 4.272

6.  Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury.

Authors:  Alexander J Leedom; Aaron B Sullivan; Baiyan Dong; Denise Lau; Karsten Gronert
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

Review 7.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

8.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Authors:  Yiping Jin; Makoto Arita; Qiang Zhang; Daniel R Saban; Sunil K Chauhan; Nan Chiang; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

Review 9.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.

Authors:  Charles N Serhan; Nan Chiang; Thomas E Van Dyke
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

10.  ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.

Authors:  P F T Cezar-de-Mello; A M Vieira; V Nascimento-Silva; C G Villela; C Barja-Fidalgo; I M Fierro
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.